Ad hoc announcement pursuant to Art. 53 LR
Related Questions
How will the strong 2025 half-year results influence BASE's short‑term price target and trading volume?
What guidance did Basilea provide for the remainder of 2025 and FY2026, and how does it compare to market expectations?
How does Basilea's performance stack up against its biotech peers, and what are the implications for relative valuation?